;PMID: 8678904
;source_file_988.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..42] = [t:0..42]
;1)sentence:[e:48..187] = [t:48..187]
;2)section:[e:191..244] = [t:191..244]
;3)section:[e:248..301] = [t:248..301]
;4)sentence:[e:305..563] = [t:305..563]
;5)sentence:[e:564..707] = [t:564..707]
;6)sentence:[e:708..842] = [t:708..842]
;7)sentence:[e:844..956] = [t:844..956]
;8)sentence:[e:957..1110] = [t:957..1110]
;9)sentence:[e:1111..1212] = [t:1111..1212]
;10)sentence:[e:1213..1380] = [t:1213..1380]
;11)sentence:[e:1381..1533] = [t:1381..1533]
;12)sentence:[e:1534..1632] = [t:1534..1632]
;13)sentence:[e:1634..1741] = [t:1634..1741]
;14)sentence:[e:1742..1988] = [t:1742..1988]
;15)section:[e:1992..2036] = [t:1992..2036]

;section 0 Span:0..42
;Biochem Pharmacol. 1996 Jul 12;52(1):21-7.
(SEC
  (FRAG (NNP:[0..7] Biochem) (NNP:[8..17] Pharmacol) (.:[17..18] .)
        (CD:[19..23] 1996) (IN:[24..27] Jul) (CD:[28..34] 12;52-LRB-)
        (CD:[34..35] 1) (-RRB-:[35..36] -RRB-) (CD:[36..39] :21) (::[39..40] -)
        (CD:[40..42] 7.)))

;sentence 1 Span:48..187
;Increased DT-diaphorase expression and cross-resistance to mitomycin C in a 
;series of cisplatin-resistant human ovarian cancer cell lines.
;[58..71]:substance:"DT-diaphorase"
;[107..118]:substance:"mitomycin C"
;[135..144]:substance:"cisplatin"
(SENT
  (NP-HLN
    (NP
      (NP (VBN:[48..57] Increased) (NN:[58..71] DT-diaphorase)
          (NN:[72..82] expression))
      (CC:[83..86] and)
      (NP
        (NP (AFX:[87..92] cross) (HYPH:[92..93] -) (NN:[93..103] resistance))
        (PP (TO:[104..106] to)
          (NP (NN:[107..116] mitomycin) (NN:[117..118] C)))))
    (PP-LOC (IN:[119..121] in)
      (NP
        (NP (DT:[122..123] a) (NN:[125..131] series))
        (PP (IN:[132..134] of)
          (NP
            (ADJP (NN:[135..144] cisplatin) (HYPH:[144..145] -)
                  (JJ:[145..154] resistant))
            (JJ:[155..160] human) (JJ:[161..168] ovarian) (NN:[169..175] cancer)
             (NN:[176..180] cell) (NNS:[181..186] lines)))))
    (.:[186..187] .)))

;section 2 Span:191..244
;O'Dwyer PJ, Perez RP, Yao KS, Godwin AK, Hamilton TC.
(SEC
  (FRAG (NNP:[191..198] O'Dwyer) (NNP:[199..201] PJ) (,:[201..202] ,)
        (NNP:[203..208] Perez) (NNP:[209..211] RP) (,:[211..212] ,)
        (NNP:[213..216] Yao) (NNP:[217..219] KS) (,:[219..220] ,)
        (NNP:[221..227] Godwin) (NNP:[228..230] AK) (,:[230..231] ,)
        (NNP:[232..240] Hamilton) (NNP:[241..243] TC) (.:[243..244] .)))

;section 3 Span:248..301
;Fox Chase Cancer Center, Philadelphia, PA 19111, USA.
(SEC
  (FRAG (NNP:[248..251] Fox) (NNP:[252..257] Chase) (NNP:[258..264] Cancer)
        (NNP:[265..271] Center) (,:[271..272] ,) (NNP:[273..285] Philadelphia)
        (,:[285..286] ,) (NNP:[287..289] PA) (CD:[290..295] 19111)
        (,:[295..296] ,) (NNP:[297..300] USA) (.:[300..301] .)))

;sentence 4 Span:305..563
;In a series of ovarian carcinoma cell lines selected in vitro for resistance
;to  cisplatin by continuous exposure to increasing drug concentrations, the
;level of  resistance is proportional to the expression of
;gamma-glutamylcysteine  synthetase (gamma-GCS).
;[386..395]:substance:"cisplatin"
;[433..437]:substance:"drug"
;[516..550]:substance:"gamma-glutamylcysteine  synthetase"
;[552..561]:substance:"gamma-GCS"
(SENT
  (S
    (PP (IN:[305..307] In)
      (NP
        (NP (DT:[308..309] a) (NN:[310..316] series))
        (PP (IN:[317..319] of)
          (NP
            (NP (JJ:[320..327] ovarian) (NN:[328..337] carcinoma)
                (NN:[338..342] cell) (NNS:[343..348] lines))
            (VP (VBN:[349..357] selected)
              (NP (-NONE-:[357..357] *))
              (ADVP (FW:[358..360] in) (FW:[361..366] vitro))
              (PP (IN:[367..370] for)
                (NP
                  (NP (NN:[371..381] resistance))
                  (PP (TO:[382..384] to)
                    (NP (NN:[386..395] cisplatin)))))
              (PP-MNR (IN:[396..398] by)
                (NP
                  (NP (JJ:[399..409] continuous) (NN:[410..418] exposure))
                  (PP (TO:[419..421] to)
                    (NP (VBG:[422..432] increasing) (NN:[433..437] drug)
                        (NNS:[438..452] concentrations))))))))))
    (,:[452..453] ,)
    (NP-SBJ
      (NP (DT:[454..457] the) (NN:[458..463] level))
      (PP (IN:[464..466] of)
        (NP (NN:[468..478] resistance))))
    (VP (VBZ:[479..481] is)
      (ADJP-PRD (JJ:[482..494] proportional)
        (PP (TO:[495..497] to)
          (NP
            (NP (DT:[498..501] the) (NN:[502..512] expression))
            (PP (IN:[513..515] of)
              (NP
                (NP (NN:[516..538] gamma-glutamylcysteine)
                    (NN:[540..550] synthetase))
                (NP (-LRB-:[551..552] -LRB-) (NN:[552..561] gamma-GCS)
                    (-RRB-:[561..562] -RRB-))))))))
    (.:[562..563] .)))

;sentence 5 Span:564..707
;To determine if other detoxicating genes are  coordinately expressed, we
;measured the activity of DT-diaphorase and cytochrome  P450 reductase.
;[662..675]:substance:"DT-diaphorase"
;[680..706]:substance:"cytochrome  P450 reductase"
(SENT
  (S
    (S-PRP
      (NP-SBJ (-NONE-:[564..564] *))
      (VP (TO:[564..566] To)
        (VP (VB:[567..576] determine)
          (SBAR (IN:[577..579] if)
            (S
              (NP-SBJ-2 (JJ:[580..585] other) (VBG:[586..598] detoxicating)
                        (NNS:[599..604] genes))
              (VP (VBP:[605..608] are)
                (ADVP (RB:[610..622] coordinately))
                (VP (VBN:[623..632] expressed)
                  (NP-2 (-NONE-:[632..632] *)))))))))
    (,:[632..633] ,)
    (NP-SBJ (PRP:[634..636] we))
    (VP (VBD:[637..645] measured)
      (NP
        (NP (DT:[646..649] the) (NN:[650..658] activity))
        (PP (IN:[659..661] of)
          (NP
            (NP (NN:[662..675] DT-diaphorase))
            (CC:[676..679] and)
            (NP
              (NML (NN:[680..690] cytochrome) (NN:[692..696] P450))
              (NN:[697..706] reductase))))))
    (.:[706..707] .)))

;sentence 6 Span:708..842
;The specific activity of DT-diaphorase, but not that of  cytochrome P450
;reductase, increased with increasing resistance to cisplatin.
;[733..746]:substance:"DT-diaphorase"
;[765..790]:substance:"cytochrome P450 reductase"
;[832..841]:substance:"cisplatin"
(SENT
  (S
    (NP-SBJ
      (NP
        (NP (DT:[708..711] The) (JJ:[712..720] specific)
            (NN:[721..729] activity))
        (PP (IN:[730..732] of)
          (NP (NN:[733..746] DT-diaphorase))))
      (,:[746..747] ,)
      (CONJP (CC:[748..751] but) (RB:[752..755] not))
      (NP
        (NP (DT:[756..760] that))
        (PP (IN:[761..763] of)
          (NP
            (NML (NN:[765..775] cytochrome) (NN:[776..780] P450))
            (NN:[781..790] reductase)))))
    (,:[790..791] ,)
    (VP (VBD:[792..801] increased)
      (PP (IN:[802..806] with)
        (NP
          (NP (VBG:[807..817] increasing) (NN:[818..828] resistance))
          (PP (TO:[829..831] to)
            (NP (NN:[832..841] cisplatin))))))
    (.:[841..842] .)))

;sentence 7 Span:844..956
;Steady-state mRNA levels for DT-diaphorase correlated with enzyme activity
;and  hence with cisplatin resistance.
;[857..861]:substance:"mRNA"
;[873..886]:substance:"DT-diaphorase"
;[903..909]:substance:"enzyme"
;[935..944]:substance:"cisplatin"
(SENT
  (S
    (NP-SBJ
      (NP
        (NML (JJ:[844..850] Steady) (HYPH:[850..851] -) (NN:[851..856] state))
        (NN:[857..861] mRNA) (NNS:[862..868] levels))
      (PP (IN:[869..872] for)
        (NP (NN:[873..886] DT-diaphorase))))
    (VP (VBD:[887..897] correlated)
      (PP-CLR
        (PP (IN:[898..902] with)
          (NP (NN:[903..909] enzyme) (NN:[910..918] activity)))
        (CC:[919..922] and)
        (PP
          (ADVP (RB:[924..929] hence))
          (IN:[930..934] with)
          (NP (NN:[935..944] cisplatin) (NN:[945..955] resistance)))))
    (.:[955..956] .)))

;sentence 8 Span:957..1110
;Since the activity of DT-diaphorase has been  associated with sensitivity to
;quinones, we studied the cytotoxicity of  mitomycin C under oxic conditions.
;[979..992]:substance:"DT-diaphorase"
;[1034..1042]:substance:"quinones"
;[1076..1087]:substance:"mitomycin C"
(SENT
  (S
    (SBAR-ADV (IN:[957..962] Since)
      (S
        (NP-SBJ-2
          (NP (DT:[963..966] the) (NN:[967..975] activity))
          (PP (IN:[976..978] of)
            (NP (NN:[979..992] DT-diaphorase))))
        (VP (VBZ:[993..996] has)
          (VP (VBN:[997..1001] been)
            (VP (VBN:[1003..1013] associated)
              (NP-2 (-NONE-:[1013..1013] *))
              (PP-CLR (IN:[1014..1018] with)
                (NP
                  (NP (NN:[1019..1030] sensitivity))
                  (PP (TO:[1031..1033] to)
                    (NP (NNS:[1034..1042] quinones))))))))))
    (,:[1042..1043] ,)
    (NP-SBJ (PRP:[1044..1046] we))
    (VP (VBD:[1047..1054] studied)
      (NP
        (NP (DT:[1055..1058] the) (NN:[1059..1071] cytotoxicity))
        (PP (IN:[1072..1074] of)
          (NP (NN:[1076..1085] mitomycin) (NN:[1086..1087] C))))
      (PP (IN:[1088..1093] under)
        (NP (JJ:[1094..1098] oxic) (NNS:[1099..1109] conditions))))
    (.:[1109..1110] .)))

;sentence 9 Span:1111..1212
;Unexpectedly, resistance to mitomycin C  increased proportionally with that
;to cisplatin (r = 0.997).
;[1139..1150]:substance:"mitomycin C"
;[1190..1199]:substance:"cisplatin"
(SENT
  (S
    (ADVP (RB:[1111..1123] Unexpectedly))
    (,:[1123..1124] ,)
    (NP-SBJ
      (NP (NN:[1125..1135] resistance))
      (PP (TO:[1136..1138] to)
        (NP (NN:[1139..1148] mitomycin) (NN:[1149..1150] C))))
    (VP (VBD:[1152..1161] increased)
      (ADVP-MNR (RB:[1162..1176] proportionally))
      (PP (IN:[1177..1181] with)
        (NP
          (NP (DT:[1182..1186] that))
          (PP (TO:[1187..1189] to)
            (NP (NN:[1190..1199] cisplatin)))))
      (PRN (-LRB-:[1200..1201] -LRB-)
        (S
          (NP-SBJ (NN:[1201..1202] r))
          (VP (SYM:[1203..1204] =)
            (NP (CD:[1205..1210] 0.997))))
        (-RRB-:[1210..1211] -RRB-)))
    (.:[1211..1212] .)))

;sentence 10 Span:1213..1380
;Pretreatment with  buthionine sulfoximine, which inhibits glutathione (GSH)
;synthesis, failed to  sensitize either the sensitive or the resistant lines
;to mitomycin C.
;[1232..1254]:substance:"buthionine sulfoximine"
;[1271..1282]:substance:"glutathione"
;[1284..1287]:substance:"GSH"
;[1368..1379]:substance:"mitomycin C"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[1213..1225] Pretreatment))
      (PP (IN:[1226..1230] with)
        (NP
          (NP (NN:[1232..1242] buthionine) (NN:[1243..1254] sulfoximine))
          (,:[1254..1255] ,)
          (SBAR
            (WHNP-2 (WDT:[1256..1261] which))
            (S
              (NP-SBJ-2 (-NONE-:[1261..1261] *T*))
              (VP (VBZ:[1262..1270] inhibits)
                (NP
                  (NML
                    (NML (NN:[1271..1282] glutathione))
                    (NML (-LRB-:[1283..1284] -LRB-) (NN:[1284..1287] GSH)
                         (-RRB-:[1287..1288] -RRB-)))
                  (NN:[1289..1298] synthesis))))))))
    (,:[1298..1299] ,)
    (VP (VBD:[1300..1306] failed)
      (S
        (NP-SBJ (-NONE-:[1306..1306] *))
        (VP (TO:[1307..1309] to)
          (VP (VB:[1311..1320] sensitize)
            (NP
              (NP (CC:[1321..1327] either)
                (NP (DT:[1328..1331] the) (JJ:[1332..1341] sensitive)
                  (NML-1 (-NONE-:[1341..1341] *P*)))
                (CC:[1342..1344] or)
                (NP (DT:[1345..1348] the) (JJ:[1349..1358] resistant)
                  (NML-1 (NNS:[1359..1364] lines))))
              (PP (TO:[1365..1367] to)
                (NP (NN:[1368..1377] mitomycin) (NN:[1378..1379] C))))))))
    (.:[1379..1380] .)))

;sentence 11 Span:1381..1533
;Thus, the  basis for collateral resistance to mitomycin C in the
;cisplatin-resistant lines  under oxic conditions is unrelated to
;overproduction of GSH.
;[1427..1438]:substance:"mitomycin C"
;[1446..1455]:substance:"cisplatin"
;[1529..1532]:substance:"GSH"
(SENT
  (S
    (ADVP (RB:[1381..1385] Thus))
    (,:[1385..1386] ,)
    (NP-SBJ
      (NP (DT:[1387..1390] the) (NN:[1392..1397] basis))
      (PP (IN:[1398..1401] for)
        (NP
          (NP (JJ:[1402..1412] collateral) (NN:[1413..1423] resistance))
          (PP (TO:[1424..1426] to)
            (NP (NN:[1427..1436] mitomycin) (NN:[1437..1438] C)))
          (PP (IN:[1439..1441] in)
            (NP (DT:[1442..1445] the)
              (ADJP (NN:[1446..1455] cisplatin) (HYPH:[1455..1456] -)
                    (JJ:[1456..1465] resistant))
              (NNS:[1466..1471] lines)))
          (PP (IN:[1473..1478] under)
            (NP (JJ:[1479..1483] oxic) (NNS:[1484..1494] conditions))))))
    (VP (VBZ:[1495..1497] is)
      (ADJP-PRD (JJ:[1498..1507] unrelated)
        (PP (TO:[1508..1510] to)
          (NP
            (NP (NN:[1511..1525] overproduction))
            (PP (IN:[1526..1528] of)
              (NP (NN:[1529..1532] GSH)))))))
    (.:[1532..1533] .)))

;sentence 12 Span:1534..1632
;Under hypoxia, the  toxicity of mitomycin C to the most sensitive (A2780)
;cell line was unchanged.
;[1566..1577]:substance:"mitomycin C"
(SENT
  (S
    (PP (IN:[1534..1539] Under)
      (NP (NN:[1540..1547] hypoxia)))
    (,:[1547..1548] ,)
    (NP-SBJ
      (NP (DT:[1549..1552] the) (NN:[1554..1562] toxicity))
      (PP (IN:[1563..1565] of)
        (NP (NN:[1566..1575] mitomycin) (NN:[1576..1577] C)))
      (PP (TO:[1578..1580] to)
        (NP (DT:[1581..1584] the)
          (ADJP (RBS:[1585..1589] most) (JJ:[1590..1599] sensitive))
          (PRN (-LRB-:[1600..1601] -LRB-)
            (NP (NN:[1601..1606] A2780))
            (-RRB-:[1606..1607] -RRB-))
          (NN:[1608..1612] cell) (NN:[1613..1617] line))))
    (VP (VBD:[1618..1621] was)
      (ADJP-PRD (JJ:[1622..1631] unchanged)))
    (.:[1631..1632] .)))

;sentence 13 Span:1634..1741
;However, the most resistant (C200) line was 2-fold more resistant to
;mitomycin C  under hypoxic conditions.
;[1678..1684]:quantitative-value:"2-fold"
;[1703..1714]:substance:"mitomycin C"
(SENT
  (S
    (ADVP (RB:[1634..1641] However))
    (,:[1641..1642] ,)
    (NP-SBJ (DT:[1643..1646] the)
      (ADJP (RBS:[1647..1651] most) (JJ:[1652..1661] resistant))
      (PRN (-LRB-:[1662..1663] -LRB-)
        (NP (NN:[1663..1667] C200))
        (-RRB-:[1667..1668] -RRB-))
      (NN:[1669..1673] line))
    (VP (VBD:[1674..1677] was)
      (ADJP-PRD
        (ADVP
          (ADVP-EXT (CD:[1678..1679] 2) (HYPH:[1679..1680] -)
                    (RB:[1680..1684] fold))
          (RBR:[1685..1689] more))
        (JJ:[1690..1699] resistant)
        (PP (TO:[1700..1702] to)
          (NP (NN:[1703..1712] mitomycin) (NN:[1713..1714] C))))
      (PP (IN:[1716..1721] under)
        (NP (JJ:[1722..1729] hypoxic) (NNS:[1730..1740] conditions))))
    (.:[1740..1741] .)))

;sentence 14 Span:1742..1988
;The coordinate overexpression of DT-diaphorase and  gamma-GCS in the
;resistant cell lines is thus associated with hypoxic cell  resistance, and
;supports the involvement of shared mechanisms of gene regulation  in the
;observed resistant phenotype.
;[1775..1788]:substance:"DT-diaphorase"
;[1794..1803]:substance:"gamma-GCS"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[1742..1745] The) (NN:[1746..1756] coordinate)
          (NN:[1757..1771] overexpression))
      (PP (IN:[1772..1774] of)
        (NP (NN:[1775..1788] DT-diaphorase) (CC:[1789..1792] and)
            (NN:[1794..1803] gamma-GCS)))
      (PP-LOC (IN:[1804..1806] in)
        (NP (DT:[1807..1810] the) (JJ:[1811..1820] resistant)
            (NN:[1821..1825] cell) (NNS:[1826..1831] lines))))
    (VP
      (VP (VBZ:[1832..1834] is)
        (ADVP (RB:[1835..1839] thus))
        (VP (VBN:[1840..1850] associated)
          (NP-1 (-NONE-:[1850..1850] *))
          (PP-CLR (IN:[1851..1855] with)
            (NP (JJ:[1856..1863] hypoxic) (NN:[1864..1868] cell)
                (NN:[1870..1880] resistance)))))
      (,:[1880..1881] ,) (CC:[1882..1885] and)
      (VP (VBZ:[1886..1894] supports)
        (NP
          (NP (DT:[1895..1898] the) (NN:[1899..1910] involvement))
          (PP (IN:[1911..1913] of)
            (NP
              (NP (VBN:[1914..1920] shared) (NNS:[1921..1931] mechanisms))
              (PP (IN:[1932..1934] of)
                (NP (NN:[1935..1939] gene) (NN:[1940..1950] regulation))))))
        (PP-LOC (IN:[1952..1954] in)
          (NP (DT:[1955..1958] the) (VBN:[1959..1967] observed)
              (JJ:[1968..1977] resistant) (NN:[1978..1987] phenotype)))))
    (.:[1987..1988] .)))

;section 15 Span:1992..2036
;PMID: 8678904 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1992..1996] PMID) (::[1996..1997] :) (CD:[1998..2005] 8678904)
        (NN:[2006..2007] -LSB-) (NNP:[2007..2013] PubMed) (::[2014..2015] -)
        (NN:[2016..2023] indexed) (IN:[2024..2027] for)
        (NNP:[2028..2036] MEDLINE-RSB-)))
